The Nanowear Wearable Covid-19 Observational and Analysis Trend

Stopped early

Conditions studied: Covid19

In brief

The NanoCOAT study is a multi-center, prospective, non-randomized, feasibility, observational, non-significant risk study. The NanoCOAT study will enroll a minimum of 10 and a maximum of 100 subjects in a potential for a multi-site in order to collect data and analyze physiological and biometric trends due to Covid-19.

Key facts

Study ID

NCT04717024

Run by

Nanowear Inc.

People needed

15

Starts

2020-09-15

Expected to finish

2021-04-30

Last updated by the study team

2026-04-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has provided informed consent
• Male or female over the age of 18 years
• The patient is currently hospitalized with a primary diagnosis of Covid-19

You may not qualify if…

• Subject is unwilling or unable to wear the vest during hospitalization.
• Subjects who are pregnant.
• Subject is intubated or admitted to ICU
• Subject has an implantable cardiac device (i.e pacemaker or internal cardioverter defibrillator)

Where it is running

• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Maimonides Medical Center — Brooklyn, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.